Guinea Jesús, Bouza Emilio
Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo no. 46, 28007 Madrid, Spain.
Future Microbiol. 2008 Dec;3(6):603-15. doi: 10.2217/17460913.3.6.603.
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality. Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven to be active in vitro against Aspergillus, Candida and Cryptococcus neoformans, the most common agents of IFIs. Furthermore, isavuconazole has a pharmacokinetic profile that allows oral and intravenous administration with no severe toxicity. In vivo data from animal models are also encouraging. However, very little information on clinical efficacy is available. Four clinical trials are currently in progress to demonstrate the safety and efficacy of isavuconazole for the treatment and prevention of IFIs. In the absence of clinical and cost data, the real possibilities of this agent as a competitor for the treatment and prevention of IFIs in the clinical setting are still unknown.
侵袭性真菌感染（IFI）是发病和死亡的重要原因。艾沙康唑（BAL4815）是一种处于临床开发后期的有前景的新型广谱三唑类药物，已证实在体外对IFI最常见的病原体曲霉、念珠菌和新型隐球菌具有活性。此外，艾沙康唑具有允许口服和静脉给药且无严重毒性的药代动力学特征。来自动物模型的体内数据也令人鼓舞。然而，关于临床疗效的信息非常少。目前正在进行四项临床试验，以证明艾沙康唑治疗和预防IFI的安全性和有效性。在缺乏临床和成本数据的情况下，该药物在临床环境中作为治疗和预防IFI的竞争药物的实际可能性仍然未知。
